<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646928</url>
  </required_header>
  <id_info>
    <org_study_id>EN-REACH</org_study_id>
    <nct_id>NCT04646928</nct_id>
  </id_info>
  <brief_title>Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients</brief_title>
  <official_title>Efficacy of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients With Compensated Cirrhosis and Low Viral Load: a Multicenter, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze the incidence of liver cancer after entecavir administration among patients with&#xD;
      low viral load and cirrhosis due to chronic hepatitis B infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To analyze the incidence of liver cancer after entecavir administration among patients with&#xD;
      low viral load (HBV DNA titer&lt;2,000 IU/mL (104 copies/mL)) and cirrhosis due to chronic&#xD;
      hepatitis B infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Anticipated">August 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>5-year Cumulative hepatocellular carcinoma incidence</measure>
    <time_frame>5 years</time_frame>
    <description>Compare the difference in the 5-year cumulative incidence of hepatocellular carcinoma in patients with chronic hepatitis B and cirrhosis with entecavir and control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Compare the difference in the 5-year incidence overall survival in patients with chronic hepatitis B and cirrhosis with entecavir and control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ascites, esophageal, gastric variceal bleeding, hepatic encephalopathy (hepatic coma)</measure>
    <time_frame>5 years</time_frame>
    <description>Compare the difference in the 5-year incidence of ascites/esophageal/gastric variceal bleeding/hepatic encephalopathy (hepatic coma) in patients with chronic hepatitis B and cirrhosis with entecavir and control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of virologic response, virologic breakthrough</measure>
    <time_frame>5 years</time_frame>
    <description>Compare the difference in the 5-year incidence incidence of virologic response and virologic breakthrough in patients with chronic hepatitis B and cirrhosis with entecavir and control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cirrhosis regression</measure>
    <time_frame>5 years</time_frame>
    <description>Compare the difference in the 5-year incidence of cirrhosis regression in patients with chronic hepatitis B and cirrhosis with entecavir and control</description>
  </secondary_outcome>
  <enrollment type="Anticipated">245</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Hepatitis B virus (HBV) DNA level from patient blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subject with Hepatitis B and liver cirrhosis displaying low viral load (HBV DNA titer&#xD;
        &lt;2,000 IU/mL (104 copies/mL))&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A subject who has consented to participate in this clinical trial&#xD;
&#xD;
          -  A subject aged between ≥20 to ≤75 years old&#xD;
&#xD;
          -  A subject with positive HBsAg for more than 24 weeks (may be confirmed by medical&#xD;
             history)&#xD;
&#xD;
          -  HBV DNA ≥26 IU/mL or ≤ 2,000 IU/mL at the time of screening&#xD;
&#xD;
          -  A subject diagnosed with cirrhosis with one of the following:&#xD;
&#xD;
               1. Subject with confirmed liver cirrhosis in the screening period or liver biopsy&#xD;
                  performed within 1 year from the time of screening (METAVIR score&gt; 3, ISHAK&#xD;
                  score&gt; 4)&#xD;
&#xD;
               2. Two or more confirmed typical findings suggesting liver cirrhosis from imaging&#xD;
                  such as liver ultrasound and CT performed within 24 weeks of screening or during&#xD;
                  screening period (nodularity of the liver surface, atrophy of the inner right and&#xD;
                  left lobes, thickening of the left and tail lobes, hepatic portal system&#xD;
                  expansion of surrounding space, expansion of hepatic portal system (&gt;1.3 cm) and&#xD;
                  splenomegaly (&gt;12 cm))&#xD;
&#xD;
               3. One or more confirmed typical findings suggesting liver cirrhosis from imaging&#xD;
                  such as liver ultrasound and CT performed within 24 weeks of screening or during&#xD;
                  screening period (nodularity of the liver surface, atrophy of the inner right and&#xD;
                  left lobes, thickening of the left and tail lobes, hepatic portal system&#xD;
                  expansion of surrounding space, expansion of hepatic portal system (&gt;1.3 cm) and&#xD;
                  splenomegaly (&gt;12 cm)) or findings including the following:&#xD;
&#xD;
          -  Confirmed thrombocytopenia (&lt;150,000/mm3) at the screening period or blood tests&#xD;
             conducted within 24 weeks from the time of screening&#xD;
&#xD;
          -  Confirmed identification of esophageal varicose veins or gastric varicose veins by&#xD;
             endoscopy or CT performed within one year from the screening period or at screening&#xD;
&#xD;
          -  Liver stiffness measurement (LSM)&gt; 11.5 kilopascal (kPa) (F4) as a result of liver&#xD;
             fibrosis scan, performed within 1 year from screening period or at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject with non compensated cirrhosis and any of the following:&#xD;
&#xD;
               1. Serum bilirubin&gt; 3 mg/dL&#xD;
&#xD;
               2. Prothrombin time&gt; 6 seconds prolonged or International Normalized Ratio (INR)&#xD;
                  &gt;1.6&#xD;
&#xD;
               3. Serum albumin &lt;2.8 g/dL&#xD;
&#xD;
               4. History of ascites, varicose bleeding, hepatorenal syndrome, hepatic&#xD;
                  encephalopathy (hepatic coma) requiring treatment within 5 years from screening&#xD;
&#xD;
               5. Child-Pugh score ≥ 8&#xD;
&#xD;
          -  A subject who have received interferon or other oral nucleic acid analogues&#xD;
             (nucleos(t)ide analogues) (However, if the treatment duration was less than 30 days in&#xD;
             the past and the treatment was treated 24 weeks before the screening, participation is&#xD;
             possible)&#xD;
&#xD;
          -  A subject diagnosed with liver cancer in the past or present&#xD;
&#xD;
          -  Renal function decline (creatinine clearance &lt;50 mL/min, estimated by the&#xD;
             Cockcroft-Gault formula)&#xD;
&#xD;
          -  A subject with serious concomitant diseases such as congestive heart failure, chronic&#xD;
             kidney disease, blood disease, or malignant tumors in the past or present&#xD;
&#xD;
          -  A subject infected with hepatitis C virus (HCV) or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  A subject who consume excessive alcohol (men: 30g/day or more, women: 20g/day or more)&#xD;
&#xD;
          -  A subject with liver diseases such as autoimmune hepatitis, hemochromatosis, or&#xD;
             Wilson's disease&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Previous organ transplant recipients&#xD;
&#xD;
          -  A subject unable to complete the clinical trial or to have any medical condition that&#xD;
             may interfere with the evaluation of the efficacy of this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SungKyu Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SungKyu Hwang, MD</last_name>
    <phone>+82-1577-4488</phone>
    <email>sghwang@cha.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jinyeong Lee</last_name>
    <phone>+82-1577-4488</phone>
    <email>or_ange@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Cheonan</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bundang Jesaeng Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea, Uijeongbu ST. Mary's Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University, Donginchoen Gil Hospital</name>
      <address>
        <city>Sŏngnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 22, 2020</last_update_submitted>
  <last_update_submitted_qc>November 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

